https://www.nasdaq.com/press-release/aptinyx-to-host-virtual-portfolio-review-event-on-february-9th-2022-2021-12-20
https://www.nasdaq.com/press-release/aptinyx-initiates-phase-2b-study-of-nyx-783-in-patients-with-post-traumatic-stress
https://www.nasdaq.com/press-release/aptinyx-to-present-at-the-40th-annual-j.p.-morgan-healthcare-conference-2021-12-13
https://www.nasdaq.com/press-release/aptinyx-to-participate-in-piper-sandler-33rd-annual-virtual-healthcare-conference
https://www.nasdaq.com/press-release/aptinyx-reports-third-quarter-2021-financial-results-and-recent-highlights-2021-11-09
https://www.nasdaq.com/press-release/aptinyx-completes-enrollment-in-phase-2b-study-of-nyx-2925-in-painful-diabetic
https://www.nasdaq.com/press-release/aptinyx-to-report-third-quarter-2021-financial-results-on-tuesday-november-9-2021
https://www.nasdaq.com/press-release/aptinyx-appoints-gilmore-oneill-m.b.-m.m.sc.-to-board-of-directors-2021-10-20
https://www.nasdaq.com/press-release/aptinyx-to-participate-in-2021-cantor-virtual-global-healthcare-conference-2021-09-20
https://www.nasdaq.com/press-release/aptinyx-secures-%2450-million-growth-capital-credit-facility-from-k2-healthventures
https://www.nasdaq.com/press-release/aptinyx-to-participate-in-h.c.-wainwright-23rd-annual-global-investment-conference
https://www.nasdaq.com/press-release/correcting-and-replacing-aptinyx-reports-second-quarter-2021-financial-results-and
https://www.nasdaq.com/press-release/aptinyx-to-participate-in-2021-wedbush-pacgrow-healthcare-virtual-conference-2021-08
https://www.nasdaq.com/press-release/aptinyx-to-report-second-quarter-2021-financial-results-on-tuesday-august-10-2021
https://www.nasdaq.com/press-release/aptinyx-to-participate-in-william-blair-biotech-focus-conference-2021-2021-07-12
https://www.nasdaq.com/press-release/aptinyx-to-participate-in-cowen-psychedelics-novel-mechanisms-in-neuropsychiatry
https://www.nasdaq.com/press-release/aptinyx-to-participate-in-upcoming-investor-conferences-2021-06-17
https://www.nasdaq.com/press-release/aptinyx-provides-update-on-nyx-783-development-program-for-the-treatment-of-post
https://www.nasdaq.com/press-release/aptinyx-reports-first-quarter-2021-financial-results-and-highlights-2021-05-13
https://www.nasdaq.com/press-release/aptinyx-appoints-joan-w.-miller-m.d.-to-board-of-directors-2021-05-10
https://www.nasdaq.com/press-release/aptinyx-to-report-first-quarter-2021-financial-results-on-thursday-may-13-2021-2021
https://www.nasdaq.com/press-release/aptinyx-presents-additional-positive-data-from-phase-2-exploratory-study-of-nyx-783
https://www.nasdaq.com/press-release/aptinyx-to-participate-in-upcoming-conferences-2021-04-27
https://www.nasdaq.com/press-release/aptinyx-recommences-phase-2-study-of-nyx-458-in-patients-with-cognitive-impairment
https://www.nasdaq.com/press-release/aptinyx-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aptinyx-to-report-fourth-quarter-and-full-year-2020-financial-results-on-wednesday
https://www.nasdaq.com/press-release/aptinyx-to-participate-in-upcoming-investor-conferences-2021-02-22
https://www.nasdaq.com/press-release/aptinyx-to-participate-at-10th-annual-svb-leerink-global-healthcare-conference-2021
https://www.nasdaq.com/press-release/aptinyx-announces-publication-of-review-article-highlighting-preclinical-data-in
https://www.nasdaq.com/press-release/aptinyx-to-participate-in-h.c.-wainwright-bioconnect-2021-conference-2021-01-05
https://www.nasdaq.com/press-release/aptinyx-announces-recommencement-of-phase-2-study-of-nyx-2925-in-patients-with
https://www.nasdaq.com/press-release/aptinyx-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference-2020-12-21
https://www.nasdaq.com/press-release/aptinyx-appoints-andy-kidd-m.d.-president-and-chief-operating-officer-2020-12-16
https://www.nasdaq.com/press-release/aptinyx-reports-third-quarter-2020-financial-results-and-recent-highlights-2020-11-12
https://www.nasdaq.com/press-release/aptinyx-to-participate-in-upcoming-virtual-investor-conferences-2020-11-10
https://www.nasdaq.com/press-release/aptinyx-to-report-third-quarter-financial-results-on-thursday-november-12-2020-2020
https://www.nasdaq.com/press-release/aptinyx-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-0
https://www.nasdaq.com/press-release/aptinyx-announces-pricing-of-public-offering-of-common-stock-2020-10-21
https://www.nasdaq.com/press-release/aptinyx-announces-proposed-public-offering-of-common-stock-2020-10-20
https://www.nasdaq.com/press-release/aptinyx-reports-positive-statistically-significant-top-line-data-from-phase-2-study
https://www.nasdaq.com/press-release/aptinyx-recommences-patient-recruitment-in-phase-2-study-of-nyx-2925-in-patients-with
https://www.nasdaq.com/press-release/aptinyx-to-present-at-upcoming-virtual-investor-conferences-2020-09-03
https://www.nasdaq.com/press-release/aptinyx-reports-second-quarter-2020-financial-results-and-highlights-2020-08-13
https://www.nasdaq.com/press-release/aptinyx-to-present-at-the-2020-wedbush-pacgrow-healthcare-virtual-conference-2020-08
https://www.nasdaq.com/press-release/aptinyx-to-report-second-quarter-financial-results-on-thursday-august-13-2020-2020-07
https://www.nasdaq.com/press-release/aptinyx-to-host-ptsd-focused-rd-day-on-august-5th-2020-2020-07-08
https://www.nasdaq.com/press-release/aptinyx-to-be-added-to-russell-2000r-index-2020-06-26
https://www.nasdaq.com/press-release/aptinyx-completes-enrollment-in-phase-2-exploratory-study-of-nyx-783-in-post
https://www.nasdaq.com/press-release/aptinyx-to-present-at-upcoming-virtual-investor-conferences-2020-06-16
https://www.nasdaq.com/press-release/aptinyx-reports-first-quarter-2020-financial-results-and-highlights-2020-05-14
https://www.nasdaq.com/press-release/aptinyx-to-report-first-quarter-financial-results-on-thursday-may-14-2020-2020-04-30
https://www.nasdaq.com/press-release/aptinyx-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/aptinyx-to-report-fourth-quarter-and-full-year-2019-financial-results-on-monday-march
https://www.nasdaq.com/press-release/aptinyx-to-present-at-upcoming-investor-conferences-2020-02-19
https://www.nasdaq.com/press-release/aptinyx-announces-publication-of-data-in-movement-disorders-demonstrating-reversal-of
https://www.nasdaq.com/press-release/aptinyx-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of
https://www.nasdaq.com/press-release/aptinyx-announces-pricing-of-public-offering-of-common-stock-2020-01-10
https://www.nasdaq.com/press-release/aptinyx-announces-proposed-public-offering-of-common-stock-2020-01-09
https://www.nasdaq.com/press-release/aptinyx-to-present-at-38th-annual-j.p.-morgan-healthcare-conference-2019-12-12
https://www.nasdaq.com/press-release/aptinyx-to-present-preclinical-data-exhibiting-effects-of-nyx-783-in-models-of-ptsd
https://www.nasdaq.com/press-release/aptinyx-initiates-phase-2-study-of-nyx-458-in-patients-with-mild-cognitive-impairment
https://www.nasdaq.com/press-release/aptinyx-to-present-at-upcoming-investor-conferences-2019-11-14
https://www.nasdaq.com/press-release/aptinyx-reports-third-quarter-2019-financial-results-and-highlights-2019-11-12
https://www.nasdaq.com/press-release/aptinyx-initiates-two-phase-2-studies-of-nyx-2925-in-patients-with-chronic
https://www.nasdaq.com/press-release/aptinyx-to-report-third-quarter-2019-financial-results-on-tuesday-november-12-2019
https://www.nasdaq.com/press-release/aptinyx-announces-results-of-phase-2-fibromyalgia-study-of-nyx-2925-have-been
https://www.nasdaq.com/press-release/aptinyx-to-present-preclinical-data-on-three-clinical-stage-nmda-receptor-modulators
https://www.nasdaq.com/press-release/lifshitz-miller-llp-announces-investigation-of-abeona-therapeutics-inc.-aptinyx-inc.
https://www.nasdaq.com/press-release/aptinyx-aptx-alert%3a-johnson-fistel-launches-investigation-into-aptinyx-inc.-investors
https://www.nasdaq.com/press-release/aptinyx-to-present-at-the-2019-cantor-fitzgerald-global-healthcare-conference-2019-09
https://www.nasdaq.com/press-release/three-recent-preclinical-publications-highlight-nmda-receptor-activation-facilitated
https://www.nasdaq.com/press-release/robust-analgesic-activity-aptinyxs-nyx-2925-advanced-dpn-patients-revealed-through
